- The FDA has granted breakthrough device designation to Abiomed Inc's ABMD Impella ECP expandable percutaneous heart pump.
- Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques. It measures 3 mm in diameter when inserted and removed from the body.
- It expands in the heart to support its pumping function and provides a flow greater than 3.5 L/min.
- Abiomed's breakthrough device designation follows the FDA's premarket approval of its Impella RP right heart pump in June.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: ABMD shares are up 1.34% at $332.97 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
